Company intelligence / Profile preview

Andros Pharmaceuticals Co., Ltd.

Ownership: Private
Development stage: Phase 2

Overview

APC101 completed Phase 2a clinical trials in Australia in 2020. APC201 is currently in Phase 1/2 clinical trials for arthritis. APC101 for head and neck postherpetic neuralgia received approval from Taiwan FDA to conduct Phase 2 clinical trials in 2024[10].

Therapeutic areas: OtherRheumatologyOncologyNeurology
Modalities: Topical drug delivery systemsNon-viral gene delivery systems
Industry: Biotech

Drug pipeline

8 assets

LTC Cream

7 more assets in the full pipeline.

Partnerships

Hong Kong pharmaceutical company (unnamed) for LALP cream

Beyond the preview

Go deeper on Andros Pharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andros Pharmaceuticals Co., Ltd..